Ariceum Therapeutics

#Ariceum is #hiring. We have an exciting opportunity for a Clinical Trial Director to lead global clinical trials with our innovative radiopharmaceutical pipeline programs, based in Basel, Berlin, or the US East Coast.   Apply to join our team as we continue to advance novel targeted #radiopharmaceuticals to visualize and treat #cancer.   Learn more here: https://lnkd.in/epBctKTg   To apply for the position please send a cover letter and full Curriculum Vitae to careers@ariceum-therapeutics.com.   #biotech #oncology #cancer #lifesciences #radiopharmaceuticals #Basel #Berlin #EastCoast

✨ This International Day of Women and Girls in Science (#STEM), we at #Ariceum are proud to celebrate our talented female colleagues who are making groundbreaking contributions to #radiopharmaceutical research! 👏 Their dedication, innovation, and expertise are driving progress in targeted cancer therapies, helping to shape the future of medicine. Today, and every day, let’s inspire, support, and empower more women in STEM—fostering inclusion and diversity to ensure that every voice is heard, valued, and empowered. Together, we can build a brighter, more innovative future. We’re proud to introduce the incredible women 👇 at Ariceum who are driving innovation, breaking barriers, and making a difference in STEM 🌟 Anika Jäkel, Head of Translational Biology and Non-Clinical Pharmacology Hella Berkhout, Clinical Trial Director Jessica Klaver Preston, Clinical Trial Director Brigitta Voss, Head of Program and Portfolio Management Marion Huber, CMC Manager CAROL ANDREA PREGONERO GAMEZ, PhD, Clinical Project Manager Theresa Neumann, Science Manager Natalie Schaut, Chemical Technical Assistant Prachi Desai, Scientist Translational Biology & Non-Clinical Pharmacology Carina Graß, Scientist Michaela Matroß, Executive Assistant & Office Manager Basel Ana Japaridze, HR Manager Anamaria Pop, Office Manager Shelby Hartzell, Regulatory Affairs Manager #biotech #oncology #cancer #lifesciences #radiopharmaceuticals

What do industry experts predict will be the biggest trends for clinical trials in 2025? 📰 Read pharmaphorum’s latest article, 'Clinical trends for 2025: A year of change' where our CEO, Manfred Ruediger provides his perspective on this topic. Considering increased activity in the #radiopharmaceutical field, Manfred confirmed “We expect further activity in the clinic as interest grows and pharma companies continue to invest in the technology.” Read more about Manfred’s views on the current clinical trial landscape and activities in the field of #radiopharmaceuticals here: https://bit.ly/4hD6vUU #biotech #oncology #cancer #lifesciences #radiopharmaceuticals 

📢 News alert from #AriceumTherapeutics! 📢 We are excited to announce that the #FDA has granted Orphan Drug Designation (#ODD) to our proprietary #radiopharmaceutical #cancer therapy, ²²⁵Ac-satoreotide.   Key points: 📌 ODD granted for ²²⁵Ac-satoreotide for the treatment of patients with Small Cell Lung Cancer (#SCLC) 📌 ODD follows outstanding preclinical data and FDA IND clearance 📌 Phase I/II human trials set to commence in Q1 2025 as a ‘theranostic’ targeted radionuclide treatment   SCLC is a deadly condition that represents a significant unmet medical need due to the limited number of treatment options available to patients with this aggressive form of cancer.   ²²⁵Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage SCLC or Merkel Cell Carcinoma (MCC). Pre-clinical data of ²²⁵Ac-satoreotide showed a high frequency of complete durable responses and 100% survival supporting advanced clinical development in SCLC, MCC, and other aggressive cancers.   To find out more about this important regulatory milestone and what it means for Ariceum, read the press release linked in the comments below.   #biotech #oncology #cancer #lifesciences #radiopharmaceuticals #IsotopeTechnology

📰 #Ariceum spotlighted in Labiotech.eu! 📰   To mark #WorldCancerDay, our Chief Medical Officer, Germo Gericke spoke with Roohi Mariam Peter at #Labiotech on the trends in #cancer therapeutics to look forward to in 2025.   Germo provided insights on the #radiopharmaceutical field, highlighting why he believes that radioligand therapy could offer a powerful new way to treat small cell lung cancer (#SCLC) by targeting the diseased tissue with radiation that can kill cancer cells and make them more susceptible to immunotherapy.   Read more about how #radiopharmaceuticals have the potential to make standard treatment more effective for SCLC in the full article here: https://bit.ly/4hms1NO   #biotech #oncology #lifesciences #IsotopeTechnology

📝 Make sure to register for tomorrow's Senn Chemicals AG 'Targeting with Precision: Dosimetry and Isotope Strategies in Radiotheranostic Advancements' webinar! Industry experts will discuss recent developments, challenges, and trends in #Theranostics.   #Ariceum's Head of CMC and Radiopharmaceutical Development, Manuel Sturzbecher-Hoehne, is joining the exclusive online webinar to provide insight into Ariceum's novel targeted #radiopharmaceutical pipeline, including our lead candidate #satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (#SSTR2).   🕟 Catch Manuel's presentation from 16:20-16:35 CET: 'Development of an SSTR2 antagonist for clinical use and how isotope choices are driven by the targeting molecule.'   Join the webinar by registering here https://bit.ly/4gtQXl0   #biotech #oncology #lifesciences  #radiopharmaceuticals #IsotopeTechnology

This #WorldCancerDay, observed annually on 4th February, we are #UnitedbyUnique as we join together to raise awareness and place people at the centre of #cancer care. Cancer is a major contributor to global mortality, causing about 1 in every 6 deaths and affecting nearly every household. 🤝 At #Ariceum, we are united in our mission to develop treatments for hard-to-treat cancers which remain a high unmet medical need, despite therapeutic advances made in the last decade. By using our innovative pipeline of novel targeted radiopharmaceuticals, we are committed to progressing our lead candidate #satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (#SSTR2). Satoreotide is being clinically developed as a ‘theranostic pair’ for the combined diagnosis and targeted radionuclide treatment of multiple indications expressing SSTR2, such as Small Cell lung Cancer (#SCLC), pancreatic cancers, Merkel Cell Carcinoma, and other aggressive cancers. In addition, we are also progressing clinical development of our Iodine-123 labelled PARP inhibitor, 123I-ATT001 in patients with recurrent glioblastoma. 🌟 By unleashing the power of #radiopharmaceuticals, we strive to create a better future for cancer patients. #biotech #oncology #lifesciences #IsotopeTechnology #UnitedByUnique

Are you attending #BioCapitalEurope 2025? The #Ariceum team will be in Amsterdam, The Netherlands, from 5-6 February joining VCs and Institutional Investors as they convene for the annual conference organised by EQT Life Sciences. Don't miss our CMO, Germo Gericke, who will participate in a panel delving into the dynamic landscape of #radiopharma and its future, whilst our CEO, Manfred Ruediger will present on #Ariceum's novel targeted #radiopharmaceutical pipeline and milestones to-date, including the recently announced FDA IND clearance of ²²⁵Ac-satoreotide which is being prepared to enter Phase I/II clinical development in patients with Small Cell Lung Cancer (#SCLC) or Merkel Cell Carcinoma (#MCC). Timings below! 🕘 09:10 CET: 'Half-Life, Full Impact: Navigating Radiopharma's Future' Panel 🕚 11:00 CET: Company Presentation, 'Therapeutics Track' Ariceum is one of approximately 40 biotech, medtech, and diagnostics companies from the Benelux and Europe meeting for the #lifesciences investment conference which explores industry trends in panels, keynotes, and workshops. We hope to see you there! #biotech #oncology #lifesciences  #radiopharmaceuticalstherapies #IsotopeTechnology #BioCapital

📰 #ScripAsks2025! 📰 Read insights from our CEO, Manfred Ruediger, in the latest instalment of Citeline’s Scrip Asks… What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering.   As we begin 2025, Manfred shares his predictions on this year’s #funding and #dealmaking environment and predictions for the rise of #radiopharma, commenting: “Radiopharmaceuticals are really coming of age and this is reflected in the predictions that the global market is going to continue to grow in 2025, and beyond. There’s also better availability of the materials needed to manufacture them thanks to a growing number of cyclotrons, accelerators, and other approaches to service the industry.”   Read more about Manfred’s views as the life science industry gears up for a busy year of partnering here: https://bit.ly/3PBHld5   #biotech #oncology #lifesciences #radiopharmaceuticaltherapies #IsotopeTechnology

📢 Exciting news from #AriceumTherapeutics! 📢 The US FDA has cleared our proprietary radiolabelled peptide, ²²⁵Ac-satoreotide, to commence a Phase I/II clinical trial in patients with Small Cell Lung Cancer (#SCLC) or Merkel Cell Carcinoma (#MCC).   Highlights: 📌 ²²⁵Ac-SSO110 (#satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonist 📌 Phase I/II SANTANA-225 study on track to enrol patients in Q1 2025   Our CMO, Germo Gericke, commented on this milestone for #Ariceum and what it means for the field of targeted radionuclide #cancer treatments: "Based on encouraging clinical data with ¹⁷⁷Lu-SSO110 and very promising pre-clinical data of ²²⁵Ac-SSO110, we are very optimistic about the potential for patients with difficult to treat cancers.”   👇 Find out more about our global, open-label Phase I/II study, in the full press release linked in the comments below!   #biotech #oncology #lifesciences #radiopharmaceuticalstherapies #IsotopeTechnology